Medicines360 Appoints Tina Raine-Bennett, MD, MPH, FACOG, as Chief Executive Officer

Dr. Raine-Bennett brings passionate expertise in improving health outcomes for women

SAN FRANCISCO – July 6, 2021 – Medicines360, a global nonprofit women’s health pharmaceutical organization, has appointed Tina Raine-Bennett, MD, MPH, FACOG, Chief Executive Officer (CEO), effective immediately, following a broad national search. With over 30 years of experience, Dr. Raine-Bennett has an extensive career of expanding research into women’s health and translating that research into clinical practice to improve health outcomes for women.

“At a time when women across the globe lack equitable access to affordable and effective medicines and care, I’m elated to join an organization working to address women’s unmet health needs by bringing affordable medicines to market,” said Dr. Raine-Bennett. “There are longstanding unfair, avoidable, yet solvable disparities in health access and outcomes for women. The uniqueness of Medicines360 is that its very existence is owed to filling these gaps to improve access to medicines for women.”

Dr. Raine-Bennett is a board-certified OB/GYN who has spent much of her career providing family planning services for teens and underserved women, and supporting efforts to help teens and young women manage their reproductive health needs. Dr. Raine-Bennett’s work has influenced policy to increase access to emergency contraception, including conducting the pivotal clinical trial that the FDA relied on to make Plan B emergency contraception available to adolescents over the counter. Prior to joining Medicines360, she served as senior staff physician and the Research Director of the Women’s Health Research Institute in the Division of Research at Kaiser Permanente Northern California, where her work in contraception and reproductive health helped improve the health outcomes of many women. She was previously a professor and clinical faculty in the Department of Obstetrics, Gynecology & Reproductive Sciences at The University of California-San Francisco at Zuckerberg San Francisco General Hospital and has over 20 years of research experience. In addition, Dr. Raine-Bennett has contributed to over 115 peer-reviewed publications, covering a wide range of women’s health topics including contraception, reproductive health disparities, cervical cancer screening, and trends in minimally invasive gynecologic surgery.

“Systemic barriers lead to widespread disparities and restrict access and choice for too many women. Equally troubling, women of color are disproportionately impacted by these barriers. Dr. Raine-Bennett’s first-hand experience caring for women in various care settings will help ensure Medicines360 continues to identify the most pressing needs in women’s health and create new models to address them,” said Leslie Benet, PhD, Professor of Bioengineering and Therapeutic Sciences and Pharmaceutical Chemistry at the University of California, San Francisco and Medicines360 Board Chair. “Dr. Raine-Bennett will further support our efforts to develop quality medicines and implement cost reduction strategies and programs that improve equitable access for women.”

Medicines360 was founded to develop new approaches for addressing unmet women’s health needs by advancing global, equitable access to critical medicines. With the appointment of Dr. Raine-Bennett as CEO, the organization will continue expanding beyond reproductive health and contraception to also address the most pressing issues affecting women globally, from HIV prevention to maternal health outcomes.

“Even in 2021, our society has yet to fully address the crises facing women’s health,” said Dr. Raine-Bennett. “Since I began practicing, the values of social equity have been at the root of my interest in medicine, and I look forward to carrying this work through in my role leading Medicines360.”

About Medicines360

Medicines360, located in San Francisco, California, is a nonprofit global women’s health pharmaceutical organization with a mission to remove cost as a barrier to health by developing and providing affordable Women’s Health products. Medicines360 is committed to working with healthcare providers, advocacy groups, and patients to deliver innovative and meaningful treatments that help women around the world have greater access to the medicines they need. For more information, visit www.medicines360.org

About Medicines360

Medicines360, located in San Francisco, California, is a nonprofit global women’s health pharmaceutical organization with a mission to catalyze equitable access to medicines and devices through product development, policy advocacy, and collaboration with global and US partners. Medicines360, through its subsidiary Impact RH360, launched the Avibela Project to expand access to hormonal IUDs in low- and middle-income countries. For more information, visit medicines360.org

Share This

AVIBELA can be made available in the following 88 countries

  1. Algeria
  2. Angola
  3. Bangladesh
  4. Belize
  5. Benin
  6. Bhutan
  7. Botswana
  8. Burkina Faso
  9. Burundi
  10. Cambodia
  11. Cameroon
  12. Cape Verde
  13. Central African Republic
  14. Chad
  15. Comoros
  16. Costa Rica
  17. Cuba
  18. Democratic Republic of the Congo
  19. Djibouti
  20. Dominica
  21. Dominican Republic
  22. Egypt
  23. El Salvador
  24. Equatorial Guinea
  25. Eritrea
  26. Ethiopia
  27. Gabon
  28. Ghana
  29. Grenada
  30. Guatemala
  31. Guinea
  32. Guinea-Bissau
  33. Haiti
  34. Honduras
  35. India
  36. Indonesia
  37. Ivory Coast
  38. Jamaica
  39. Kenya
  40. Lao PDR
  41. Lesotho
  42. Liberia
  43. Libya
  44. Madagascar
  45. Malawi
  46. Malaysia
  47. Maldives
  48. Mali
  49. Mauritania
  50. Mauritius
  51. Mayotte
  52. Morocco
  53. Mozambique
  54. Myanmar
  55. Namibia
  56. Nepal
  57. Nicaragua
  58. Niger
  59. Nigeria
  60. Pakistan
  61. Panama
  62. Papua New Guinea
  63. Philippines
  64. Republic of the Congo
  65. Rwanda
  66. Sao Tome and Principe
  67. Senegal
  68. Seychelles
  69. Sierra Leone
  70. Somalia
  71. South Africa
  72. South Sudan
  73. Sri Lanka
  74. Kitts and Nevis
  75. Lucia
  76. Vincent & the Grenadines
  77. Sudan
  78. Swaziland
  79. Tanzania
  80. Thailand
  81. The Gambia
  82. Timor-Leste
  83. Togo
  84. Tunisia
  85. Uganda
  86. Vietnam
  87. Zambia
  88. Sri Lanka

Tina Raine-Bennett, MD, MPH, FACOG

Chief Executive Officer

Tina Raine-Bennett, MD, MPH, is CEO of Medicines360. Previously, she served as a senior research scientist at the Kaiser Permanente Northern California Division of Research and the research director of the Women’s Health Research Institute. She is a Board-Certified Obstetrician Gynecologist who received her medical training at the University of California, San Diego, and post-graduate residency training and MPH at the University of Washington in Seattle, where she also completed a Robert Wood Johnson Clinical Scholars Fellowship. She was also senior staff physician at Kaiser Permanente and has a special interest in family planning and adolescent reproductive health.

As the director of the Women’s Health Research Institute, Dr. Raine-Bennett focused on expanding research on women’s health within the Division and translating women’s health research into clinical practice and policy within the Ob/Gyn departments in Northern California. She also promoted the involvement of clinicians in research designed to improve the health outcomes and healthcare experiences of women at Kaiser Permanente and women in general.

Prior to Kaiser Permanente, Dr. Raine-Bennett was a professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at University of California, San Francisco (UCSF). She was based at San Francisco General Hospital where she was also the medical director of the New Generation Health Center, a UCSF affiliate site that provides community-based reproductive health services. Dr. Raine-Bennett’s research has focused on contraceptive methods and on elucidating factors that influence contraceptive choice and continuation, and she was principal investigator on NIH grants to assess hormonal contraceptive use predictors and develop interventions to improve contraceptive access.

Her past and current research on emergency contraception has focused on the safety of making emergency contraception more accessible and she conducted a pivotal clinical trial to make emergency contraception available to teens without a prescription. She served on the editorial board of Obstetrics and Gynecology and has over 100 peer-reviewed publications. She was the Treasurer of the Board of Directors for the Society of Family Planning and Society of Family Planning Research Fund. She has also served as an examiner for the American Board of Obstetrics and Gynecology, and on national committees for the American College of Obstetrics and Gynecology and the National Medical Board of Planned Parenthood Federation of America.